Sponsor Pipeline

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
2
Recruiting
2
Phase 3
3
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-31 NCT07693426
Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents		 Recruitment opened
Active Trials by Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06900075 Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients Type 2 Diabetes Not Yet Recruiting
Phase 2/3
NCT06921486 The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects… Obesity and Overweight Active, Not Recruiting
Phase 2
NCT07114419 The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE） Obesity and Overweight Recruiting
Phase 1
NCT07693426 Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents Adolescence Obesity Recruiting
NCT07518121 A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil Diabete Type 2 Not Yet Recruiting
Disease Areas
Obesity (3) Type 2 Diabetes (1) Diabetes (1)
Get alerts when Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free